Sort   by:  
 Page size 
UnknownHumoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
Not available
S-EPMC8577228 | biostudies-literature
UnknownRepeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients.
Not available
S-EPMC8506143 | biostudies-literature
UnknownThe effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study.
Not available
S-EPMC8266273 | biostudies-literature
UnknownBoosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer.
Not available
S-EPMC7614214 | biostudies-literature
UnknownImpaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
Not available
S-EPMC9024068 | biostudies-literature
UnknownThe effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
Not available
S-EPMC9560610 | biostudies-literature
UnknownBroad and potent neutralizing antibodies are elicited in vaccinated individuals following Delta/BA.1 breakthrough infection.
Not available
S-EPMC10653880 | biostudies-literature
UnknownChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.
Not available
S-EPMC9010245 | biostudies-literature
UnknownThird-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders.
Not available
S-EPMC9472701 | biostudies-literature
UnknownHumoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
Not available
S-EPMC8506107 | biostudies-literature
Sort   by:  
 Page size